Zobrazeno 1 - 3
of 3
pro vyhledávání: '"Lori Keys Pender"'
Publikováno v:
Journal of Clinical Oncology. 37:e18249-e18249
e18249 Background: The indications and use of immune checkpoint inhibitors (ICIs) in the treatment of advanced and metastatic lung cancer have grown dramatically since the first lung cancer drug approval in 2015. The rapid pace of change can make it
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::0768de52123b831685c4903bd5db3e0e
https://doi.org/10.1200/jco.2019.37.15_suppl.e18249
https://doi.org/10.1200/jco.2019.37.15_suppl.e18249
Autor:
Jacqueline Gearhart, Jeffrey S. Weber, Charlotte Warren, Haleh Kadkhoda, Patti Repetto, Lori Keys Pender, Katie S. Lucero
Publikováno v:
Journal of Clinical Oncology. 37:e18224-e18224
e18224 Background: Immune checkpoint inhibitors (ICIs) are increasingly used in oncology care and produce a wide variety of immune-related adverse events (irAEs) that differ from toxicities of other systemic therapies. The objective of this study was
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::d838c77254eca0bb9c567e72bae41712
https://doi.org/10.1200/jco.2019.37.15_suppl.e18224
https://doi.org/10.1200/jco.2019.37.15_suppl.e18224
Autor:
Lori Keys Pender, Richard Caracio
Publikováno v:
Journal of Clinical Oncology. 37:78-78
78 Background: Immune checkpoint inhibitors (ICIs) produce a wide variety of imAEs that differ dramatically from chemotherapy adverse events. This study assessed whether online CME activities improve the knowledge, competence, and confidence of commu
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::37efa3b80dfe3687df8647233b61b609
https://doi.org/10.1200/jco.2019.37.8_suppl.78
https://doi.org/10.1200/jco.2019.37.8_suppl.78